RecruitingPhase 2Phase 3NCT07095842

Prehospital Early Administration of Ketamine for Status Epilepticus in Epileptic Kids (PEAK-SEEK)

Efficacy of Add-on Ketamine With Second-dose Midazolam for Prehospital Treatment of Epileptic Children With Status Epilepticus

Sponsor

Sohag University

Enrollment

668 participants

Start Date

Aug 3, 2025

Study Type

INTERVENTIONAL

Conditions

Convulsive Status EPILEPTICUS

Summary

The goal of this pragmatic, decentralized, pre-consented, event-driven, randomized controlled trial is to investigate the efficacy of add-on ketamine to second-dose midazolam for prehospital treatment of epileptic children with convulsive status epilepticus.

Eligibility

Min Age: 2 YearsMax Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ketamine and a drug called Midazolam for people with convulsive status epilepticus. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years to 16 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGKetamine

Intramuscular ketamine 2 mg/kg (max 90 mg)

DRUGMidazolam

Intramuscular midazolam 0.2 mg/kg (max 10 mg)

Locations(1)

Department of Pediatrics at Sohag University Hospital

Sohag, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07095842